Single-nucleus chromatin accessibility profiling highlights distinct astrocyte signatures in progressive supranuclear palsy and corticobasal degeneration.
Astrocytes
Corticobasal degeneration
Neurodegeneration
Progressive supranuclear palsy
Tauopathy
snATAC-seq
Journal
Acta neuropathologica
ISSN: 1432-0533
Titre abrégé: Acta Neuropathol
Pays: Germany
ID NLM: 0412041
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
15
06
2022
accepted:
08
08
2022
revised:
03
08
2022
pubmed:
18
8
2022
medline:
15
9
2022
entrez:
17
8
2022
Statut:
ppublish
Résumé
Tauopathies such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) exhibit characteristic neuronal and glial inclusions of hyperphosphorylated Tau (pTau). Although the astrocytic pTau phenotype upon neuropathological examination is the most guiding feature in distinguishing both diseases, regulatory mechanisms controlling their transitions into disease-specific states are poorly understood to date. Here, we provide accessible chromatin data of more than 45,000 single nuclei isolated from the frontal cortex of PSP, CBD, and control individuals. We found a strong association of disease-relevant molecular changes with astrocytes and demonstrate that tauopathy-relevant genetic risk variants are tightly linked to astrocytic chromatin accessibility profiles in the brains of PSP and CBD patients. Unlike the established pathogenesis in the secondary tauopathy Alzheimer disease, microglial alterations were relatively sparse. Transcription factor (TF) motif enrichments in pseudotime as well as modeling of the astrocytic TF interplay suggested a common pTau signature for CBD and PSP that is reminiscent of an inflammatory immediate-early response. Nonetheless, machine learning models also predicted discriminatory features, and we observed marked differences in molecular entities related to protein homeostasis between both diseases. Predicted TF involvement was supported by immunofluorescence analyses in postmortem brain tissue for their highly correlated target genes. Collectively, our data expand the current knowledge on risk gene involvement (e.g., MAPT, MAPK8, and NFE2L2) and molecular pathways leading to the phenotypic changes associated with CBD and PSP.
Identifiants
pubmed: 35976433
doi: 10.1007/s00401-022-02483-8
pii: 10.1007/s00401-022-02483-8
pmc: PMC9468099
doi:
Substances chimiques
Chromatin
0
tau Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
615-635Informations de copyright
© 2022. The Author(s).
Références
Neuropathology. 2014 Dec;34(6):555-70
pubmed: 25124031
Front Neurosci. 2019 Jan 24;13:2
pubmed: 30733664
Redox Biol. 2017 Oct;13:444-451
pubmed: 28704727
Nat Genet. 2019 Apr;51(4):683-693
pubmed: 30858613
Biosci Rep. 2015 Apr 22;35(3):
pubmed: 26182361
Nat Rev Drug Discov. 2021 Jan;20(1):39-63
pubmed: 33077936
J Exp Med. 2014 Jul 28;211(8):1689-702
pubmed: 24980047
Nat Methods. 2013 Dec;10(12):1213-8
pubmed: 24097267
Nat Genet. 2021 Mar;53(3):392-402
pubmed: 33589840
Nat Rev Genet. 2019 Apr;20(4):207-220
pubmed: 30675018
Neurobiol Dis. 2009 Apr;34(1):95-106
pubmed: 19162185
J Neuropathol Exp Neurol. 2002 Nov;61(11):935-46
pubmed: 12430710
Acta Neuropathol. 2021 May;141(5):681-696
pubmed: 33609158
PLoS One. 2020 Mar 24;15(3):e0230026
pubmed: 32208437
Nat Neurosci. 2014 Mar;17(3):357-66
pubmed: 24464041
Mol Cell. 2018 Sep 6;71(5):858-871.e8
pubmed: 30078726
J Biomed Sci. 2020 Jan 6;27(1):18
pubmed: 31906949
J Clin Psychiatry. 2009 Jun;70(6):922-31
pubmed: 19573486
Brain Pathol. 2021 Jul;31(4):e12914
pubmed: 33089580
J Neuropathol Exp Neurol. 2001 May;60(5):403-10
pubmed: 11379815
Alzheimers Dement. 2016 Oct;12(10):1040-1050
pubmed: 27686274
Cell Stem Cell. 2018 Oct 4;23(4):557-571.e8
pubmed: 30290178
Sci Rep. 2016 Apr 26;6:24933
pubmed: 27112200
Acta Neuropathol. 2006 Apr;111(4):341-50
pubmed: 16496165
Sci Rep. 2018 Jun 11;8(1):8868
pubmed: 29892006
J Neuroinflammation. 2020 Jul 13;17(1):208
pubmed: 32660586
Acta Neuropathol Commun. 2016 Mar 02;4:22
pubmed: 26936765
Mov Disord. 2014 Apr;29(4):470-8
pubmed: 24532007
Nat Genet. 2016 Jan;48(1):12-21
pubmed: 26618344
Nat Genet. 2011 Jun 19;43(7):699-705
pubmed: 21685912
Acta Neuropathol. 2019 Nov;138(5):705-727
pubmed: 31203391
Nat Commun. 2021 Feb 26;12(1):1337
pubmed: 33637727
J Neurochem. 2000 Apr;74(4):1587-95
pubmed: 10737616
Nature. 2019 Jun;570(7761):332-337
pubmed: 31042697
Rev Neurol (Paris). 2018 Nov;174(9):664-668
pubmed: 30098799
Neuron. 2004 Jul 8;43(1):57-67
pubmed: 15233917
Nat Neurosci. 2019 Dec;22(12):2087-2097
pubmed: 31768052
Science. 2016 Jun 24;352(6293):1586-90
pubmed: 27339989
Neuron. 2021 May 19;109(10):1657-1674.e7
pubmed: 33831349
Neurology. 2013 Jan 29;80(5):496-503
pubmed: 23359374
Nat Rev Genet. 2009 Apr;10(4):252-63
pubmed: 19274049
Arch Neurol. 2001 Aug;58(8):1233-9
pubmed: 11493163
Nature. 2012 Sep 6;489(7414):75-82
pubmed: 22955617
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Clin Neurol Neurosurg. 2016 Jul;146:35-9
pubmed: 27136096
Front Mol Neurosci. 2020 Oct 16;13:586731
pubmed: 33177989
Nucleic Acids Res. 2020 Jan 8;48(D1):D845-D855
pubmed: 31680165
Nat Commun. 2020 Nov 30;11(1):6129
pubmed: 33257666
Front Neurol. 2020 Nov 12;11:590199
pubmed: 33304310
Nat Commun. 2020 Mar 5;11(1):1201
pubmed: 32139671
J Exp Med. 2018 Sep 3;215(9):2355-2377
pubmed: 30108137
Lancet Neurol. 2021 Feb;20(2):107-116
pubmed: 33341150
Biochim Biophys Acta. 2015 Jul;1852(7):1219-29
pubmed: 25772164
Acta Neuropathol Commun. 2017 Nov 29;5(1):89
pubmed: 29187256
PLoS Biol. 2011 Apr;9(4):e1001046
pubmed: 21526222
Brain Pathol. 2017 Sep;27(5):645-674
pubmed: 28804999
Nat Commun. 2015 Jun 16;6:7247
pubmed: 26077951
Genome Res. 2016 Jul;26(7):990-9
pubmed: 27197224
Nat Genet. 2020 May;52(5):482-493
pubmed: 32341526
Brain Behav Immun. 2017 Mar;61:1-11
pubmed: 27395435
J Neuropathol Exp Neurol. 1996 Jan;55(1):97-105
pubmed: 8558176
Science. 2019 Nov 29;366(6469):1134-1139
pubmed: 31727856
Acta Neuropathol. 2018 Nov;136(5):709-727
pubmed: 30136084